{"product_id":"gkos-vrio-analysis","title":"Glaukos Corporation (GKOS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Glaukos Corporation (GKOS)'s competitive advantage as we dissect its core assets through the rigorous VRIO framework. This analysis distills whether its current resources are truly Valuable, Rare, Inimitable, and Organized to secure lasting market success. Dive in below to discover the definitive verdict on Glaukos Corporation (GKOS)'s true potential and strategic positioning.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 1. Proprietary iDose TR Platform (Intracameral Drug Delivery)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the engine driving Glaukos Corporation’s recent acceleration, and frankly, it’s a game-changer for chronic eye disease management. The Proprietary iDose TR Platform isn't just another drug; it’s a procedural pharmaceutical that delivers medication right where it’s needed, for a long time. This directly tackles the biggest headache in glaucoma care: patients forgetting their drops.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The core value proposition is sustained therapy for up to $\\mathbf{36 \\text{ months}}$ from a single procedure, which is huge for patient compliance and outcomes. This positions Glaukos to capture a significant piece of the $\\mathbf{\\$3.8 \\text{ billion}}$ U.S. dropless market opportunity you mentioned. The numbers from the first three quarters of fiscal 2025 show this is translating into real revenue; U.S. Glaucoma sales hit $\\mathbf{\\$80.8 \\text{ million}}$ in Q3 alone, with iDose TR contributing $\\mathbf{\\$40 \\text{ million}}$ of that. That’s a massive chunk of their $\\mathbf{\\$133.5 \\text{ million}}$ total Q3 revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes, it is rare, at least for now. As a first-of-its-kind, long-duration, intracameral procedural pharmaceutical, nothing else on the market offers this exact combination of sustained delivery and application method. It’s a true first-mover advantage in this specific therapeutic niche. The company raised its full-year 2025 net sales guidance to $\\mathbf{\\$490 \\text{ million} \\text{ to } \\$495 \\text{ million}}$ based on this momentum, signaling strong market acceptance of this unique offering.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Imitating iDose TR is tough, and that’s what creates a moat. It requires more than just a new drug molecule; you need complex drug formulation, seamless device integration to ensure the $\\mathbf{75 \\text{ mcg}}$ of travoprost continuously elutes over years, and, critically, multi-year clinical data to back up the safety and efficacy claims. Building that entire ecosystem takes serious time and capital. What this estimate hides is the time it takes for competitors to generate comparable long-term data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Glaukos is definitely organized to capitalize on this. They are successfully scaling physician training and aggressively pursuing market access. For instance, by Q2 2025, over $\\mathbf{80\\%}$ of iDose volume came from Medicare Administrative Contractor (MAC) regions with established professional fee schedules, showing their commercial team is getting the necessary reimbursement infrastructure in place. Plus, they finished Q3 2025 with $\\mathbf{\\$277.5 \\text{ million}}$ in cash and no debt, giving them the financial runway to keep pushing this platform hard.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e This all adds up to a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. The combination of proprietary technology, the clinical data package, and the established first-mover status creates a significant barrier to entry. They are already building the next generation, like iDose TREX, which only reinforces this lead. Here’s the quick math on their Glaucoma segment growth driving this:\u003c\/p\u003e\n\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric (Fiscal 2025)\u003c\/td\u003e\n    \u003ctd\u003eQ1 2025 Value\u003c\/td\u003e\n    \u003ctd\u003eQ2 2025 Value\u003c\/td\u003e\n    \u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eU.S. Glaucoma Net Sales\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$59.1 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$72.3 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$80.8 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eiDose TR Sales Contribution\u003c\/td\u003e\n    \u003ctd\u003eImplied significant driver\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$31 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$40 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eU.S. Glaucoma YoY Growth\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e41%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e57%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe trajectory is clear: the market is adopting this platform rapidly, and the structural advantages are defintely hard to replicate. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 2. Corneal Cross-Linking (CXL) Intellectual Property\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Owns the only FDA-approved CXL therapy (Photrexa) using a proprietary bio-activated pharmaceutical for keratoconus, generating $23.3 million in Corneal Health net revenues in Q3 2025, with U.S. Photrexa net sales accounting for $20.3 million of that amount. The company secured FDA approval for its next-generation, incision-free therapy, Epioxa, on October 20, 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePhotrexa (Epi-off)\u003c\/th\u003e\n\u003cth\u003eEpioxa (Epi-on)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Status\u003c\/td\u003e\n\u003ctd\u003eFirst \u0026amp; Only FDA-Approved CXL (Since 2016)\u003c\/td\u003e\n\u003ctd\u003eFirst FDA-Approved Incision-Free CXL (Approved October 20, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Sales Contribution\u003c\/td\u003e\n\u003ctd\u003e$20.3 million (U.S. component)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Expected Commercial Availability Q1 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Efficacy Endpoint (Kmax Change vs. Sham)\u003c\/td\u003e\n\u003ctd\u003eMeets definition of success: $\\ge$1 D difference at 12 months\u003c\/td\u003e\n\u003ctd\u003e–1.0 diopter (D) (p\u0026lt;0.0001) at 12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Success Rate (Keratoconus, 12 Months)\u003c\/td\u003e\n\u003ctd\u003e94% of treated eyes showed improvement or remained within 2.00 D of baseline Kmax\u003c\/td\u003e\n\u003ctd\u003eData from 2 Phase 3 pivotal trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes, the regulatory approval and proprietary formulation for CXL are unique in the U.S. market. Photrexa received orphan drug approval in 2016 as the first and only FDA-approved CXL therapy. Epioxa is the first FDA-approved topical drug therapy for keratoconus that does not require removal of the corneal epithelium.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003ePhotrexa received orphan drug approval in 2016.\u003c\/li\u003e\n\u003cli\u003eEpioxa Phase 3 trials randomized a total of over 400 patients.\u003c\/li\u003e\n\u003cli\u003eEpioxa achieved a –1.0 D Kmax treatment effect versus sham at 12 months.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; competitors face significant regulatory and clinical hurdles to replicate the approved therapy. The existing platform is supported by more than 300 peer-reviewed publications.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company has successfully advanced next-generation therapy (Epioxa) to FDA approval on October 20, 2025, with commercial availability anticipated in Q1 2026.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the approval of Epioxa secures a dominant position by offering a superior, incision-free alternative to the existing Photrexa product, leveraging the established 300+ publication base.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 3. Interventional Glaucoma (IG) \/ MIGS Portfolio\n\u003c\/h2\u003e\n\u003cp\u003eThe Interventional Glaucoma (IG) \/ MIGS Portfolio assessment is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Justification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eiStent infinite gained \u003cstrong\u003eEU MDR\u003c\/strong\u003e clearance, opening a \u003cstrong\u003e$400 million\u003c\/strong\u003e European market for standalone procedures.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eMIGS is competitive; however, the depth of the portfolio and specific regulatory clearances are not easily matched.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eDevices are subject to reverse-engineering; established surgeon base and adoption curve present higher barriers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eInternational team scaling adoption, evidenced by \u003cstrong\u003e20%\u003c\/strong\u003e YoY growth in Q3 2025 international glaucoma sales (reaching \u003cstrong\u003e$29.4 million\u003c\/strong\u003e).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eCompetitors such as Alcon and Johnson \u0026amp; Johnson Vision are active; Glaukos leads in standalone therapy positioning.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers a suite of MIGS devices, like iStent Infinite, which gained \u003cstrong\u003eEU MDR\u003c\/strong\u003e clearance, opening a \u003cstrong\u003e$400 million\u003c\/strong\u003e European market for standalone procedures. The iStent infinite is indicated for use in a standalone procedure to reduce elevated IOP in patients with primary open-angle glaucoma uncontrolled by prior medical and surgical therapy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; MIGS is competitive, but the specific portfolio depth and regulatory clearances are not easily matched.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; devices can be reverse-engineered, but the established surgeon base is harder to copy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the international team is scaling adoption, showing \u003cstrong\u003e20%\u003c\/strong\u003e YoY growth in Q3 2025 international glaucoma sales. International Glaucoma Franchise Net Sales were \u003cstrong\u003e$29.4 million\u003c\/strong\u003e in Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; competitors like Alcon and Johnson \u0026amp; Johnson Vision are active, but Glaukos leads in standalone therapy positioning.\u003c\/p\u003e\n\u003cp\u003eFurther details on the portfolio performance in Q3 2025 include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGlaucoma record net sales of \u003cstrong\u003e$110.2 million\u003c\/strong\u003e in Q3 2025, an increase of \u003cstrong\u003e45%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eU.S. Glaucoma record net sales of \u003cstrong\u003e$80.8 million\u003c\/strong\u003e in Q3 2025, an increase of \u003cstrong\u003e57%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eThe iStent infinite system includes three heparin-coated titanium stents.\u003c\/li\u003e\n\u003cli\u003eThe iStent inject W is indicated for the reduction of IOP in adult patients with mild-to-moderate primary open-angle glaucoma undergoing concomitant cataract surgery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 4. Robust Ophthalmic Pipeline Depth\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides multiple future revenue layers beyond current glaucoma dominance, with Glaucoma net sales reaching \u003cstrong\u003e$103.5 million\u003c\/strong\u003e in Q2 2025, and pipeline programs including iDose TREX in Phase \u003cstrong\u003e2b\/3 trials\u003c\/strong\u003e and GLK-401 in Phase \u003cstrong\u003e2\u003c\/strong\u003e clinical development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes; the breadth across three major disease categories, including Corneal Health net revenues of approximately \u003cstrong\u003e$20.6 million\u003c\/strong\u003e in Q2 2025, is rare for a company of its size.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires sustained, high-level R\u0026amp;D investment over many years, with Q2 2025 Research and development expenses totaling \u003cstrong\u003e$36.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; R\u0026amp;D spend increased \u003cstrong\u003e6%\u003c\/strong\u003e in Q2 2025 compared to Q2 2024, showing commitment to pipeline advancement while maintaining approximately \u003cstrong\u003e$278.6 million\u003c\/strong\u003e in cash and cash equivalents at the end of Q2 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; a deep pipeline is the classic long-term moat in MedTech\/Pharma.\u003c\/p\u003e\n\u003cp\u003eKey Pipeline Assets and Status:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram\u003c\/td\u003e\n\u003ctd\u003eDisease Focus\u003c\/td\u003e\n\u003ctd\u003eDevelopment Stage\/Key Date\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Sales (If Applicable)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eiDose TR\u003c\/td\u003e\n\u003ctd\u003eGlaucoma\u003c\/td\u003e\n\u003ctd\u003eGenerating \u003cstrong\u003e$31 million\u003c\/strong\u003e in Q2 2025 sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiDose TREX\u003c\/td\u003e\n\u003ctd\u003eGlaucoma\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e2b\/3\u003c\/strong\u003e trials\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpioxa\u003c\/td\u003e\n\u003ctd\u003eCornea (Keratoconus)\u003c\/td\u003e\n\u003ctd\u003eFDA PDUFA date set for \u003cstrong\u003eOctober 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLK-401\u003c\/td\u003e\n\u003ctd\u003eRetina (Wet AMD)\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e2\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePRESERFLO MicroShunt\u003c\/td\u003e\n\u003ctd\u003eGlaucoma\u003c\/td\u003e\n\u003ctd\u003ePivotal U.S. trials; potential U.S. approval around \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePipeline Investment Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGAAP and non-GAAP Research and development (R\u0026amp;D) expenses for Q2 2025: \u003cstrong\u003e$36.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eYear-over-year R\u0026amp;D expense increase for Q2 2025: \u003cstrong\u003e6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eU.S. Glaucoma net sales in Q2 2025: \u003cstrong\u003e$72.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 5. Strong, Debt-Free Balance Sheet\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides financial flexibility to fund pipeline development and navigate reimbursement complexities without interest expense pressure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes; many growth-focused MedTech firms carry significant debt loads.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires years of disciplined financial management and successful capital raises.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management has clearly prioritized capital preservation while investing for growth.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this financial structure is a major advantage in uncertain reimbursement environments.\u003c\/p\u003e\n\n\u003cp\u003eThe company's financial position at the end of the third quarter of 2025 demonstrates this strength:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount (Q3 2025 End)\u003c\/th\u003e\n\u003cth\u003eContext\/Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents (Total Liquidity)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$277.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnded Q3 2025 with this amount.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported as no debt outstanding at quarter-end.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e (Implied)\u003c\/td\u003e\n\u003ctd\u003eSignificantly lower than the Medical Devices sector average of \u003cstrong\u003e8.0%\u003c\/strong\u003e (Debt\/EV) or \u003cstrong\u003e1.9%\u003c\/strong\u003e (Debt\/EBITDA) as of Q3 2023.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Net Sales Guidance (Raised)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$490 million to $495 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from a previous range of $480 million to $486 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreliminary 2026 Net Sales Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$600 million to $620 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIntroduced preliminary outlook.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe absence of debt provides a distinct advantage when compared to industry trends:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal medtech financing in the year ending June 30, 2023, was largely driven by a \u003cstrong\u003e72% jump in industry debt\u003c\/strong\u003e, which rose to US$19 billion.\u003c\/li\u003e\n\u003cli\u003eFor comparison, a large MedTech peer, Alcon, reported a Debt-to-Equity ratio of \u003cstrong\u003e0.24\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnother MedTech firm, CeriBell, reported a Debt-to-Equity ratio of \u003cstrong\u003e0.12\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis capital structure supports current operational performance and future investment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Net Sales reached a record \u003cstrong\u003e$133.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eiDoseTR sales in Q3 2025 were approximately \u003cstrong\u003e$40 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eU.S. Glaucoma franchise net sales were \u003cstrong\u003e$80.8 million\u003c\/strong\u003e in Q3 2025, a \u003cstrong\u003e57%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eGAAP Research and Development (R\u0026amp;D) expenses for Q3 2025 were \u003cstrong\u003e$38.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 6. High Product Gross Margins\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High margins allow for aggressive reinvestment into commercial expansion and R\u0026amp;D while maintaining profitability potential. Non-GAAP gross margin hit \u003cstrong\u003e~84%\u003c\/strong\u003e in Q3 2025. The company is managing cost of revenue effectively as sales scale, evidenced by margin expansion year-over-year.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; high for a device\/pharma hybrid, but not entirely unique in the specialized medical device space.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; manufacturing processes can be optimized, but proprietary drug delivery systems often command premium margins.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company is successfully managing cost of revenue as sales scale, which is reflected in the margin progression.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; margins can compress as competition enters or supply costs rise.\u003c\/p\u003e\n\u003cp\u003eThe financial performance supporting this high-margin structure is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Sales (Millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$133.5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$96.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Gross Margin (%)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~78%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~77%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Gross Margin (%)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~84%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~82%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Gross Profit (Millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$104.706\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImplied: ~$74.46\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of Sales (Millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.831\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImplied: ~$22.24\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe increase in Non-GAAP gross margin from \u003cstrong\u003e~82%\u003c\/strong\u003e in Q3 2024 to \u003cstrong\u003e~84%\u003c\/strong\u003e in Q3 2025, alongside a \u003cstrong\u003e38%\u003c\/strong\u003e increase in reported net sales to \u003cstrong\u003e$133.5 million\u003c\/strong\u003e in Q3 2025, demonstrates successful operational leverage.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics related to margin and scale in Q3 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet sales reached a record of \u003cstrong\u003e$133.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGlaucoma net sales were a record \u003cstrong\u003e$110.2 million\u003c\/strong\u003e, a \u003cstrong\u003e45%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eU.S. Glaucoma net sales were a record \u003cstrong\u003e$80.8 million\u003c\/strong\u003e, a \u003cstrong\u003e57%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eGAAP Research and Development (R\u0026amp;D) expenses increased \u003cstrong\u003e10%\u003c\/strong\u003e to \u003cstrong\u003e$38.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company ended Q3 2025 with approximately \u003cstrong\u003e$277.5 million\u003c\/strong\u003e in cash and cash equivalents, short-term investments and restricted cash, and no debt.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 7. First-Mover Advantage in Procedural Drug Delivery\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eU.S. Glaucoma net sales reached $80.8 million in Q3 2025, with iDose TR contributing approximately $40 million in Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe iDose TR received FDA approval in December 2023 and was commercially launched to the U.S. market in March 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe permanent J-code (J7355) for iDose TR took effect on July 1, 2024.\u003c\/p\u003e\n\u003cp\u003eBy the summer of 2025, Glaukos had convinced four of the seven Medicare Administrative Contractors (MACs) in the U.S. to resume insurance coverage for its devices and surgical procedures.\u003c\/p\u003e\n\u003cp\u003eIn Q2 2025, 80% of iDose TR sales originated from the regions of the three MACs that had resumed payments.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company raised its full-year 2025 net sales guidance to a range of $490 million to $495 million.\u003c\/p\u003e\n\u003cp\u003ePreliminary 2026 net sales guidance was introduced in the range of $600 million to $620 million.\u003c\/p\u003e\n\u003cp\u003eGlaukos ended the third quarter of 2025 with approximately $277.5 million in cash and no debt.\u003c\/p\u003e\n\u003cp\u003eGlaukos is in discussions with MACs regarding expanded insurance coverage, with expected progress by early 2026.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eAt 36 months post-implantation in Phase 3 pivotal trials, approximately 70% of iDose TR patients remained well-controlled on the same or fewer IOP-lowering topical medications, compared to 58% of timolol control subjects.\u003c\/p\u003e\n\u003cp\u003eIn controlled studies, 81% of iDose TR subjects were completely free of IOP-lowering topical medication at 12 months.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eMetric\/Data Point\u003c\/td\u003e\n\u003ctd\u003eValue\/Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue Driver\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 iDose TR Contribution to U.S. Glaucoma Sales\u003c\/td\u003e\n\u003ctd\u003eApproximately $40 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity Driver\u003c\/td\u003e\n\u003ctd\u003eFDA Approval Date\u003c\/td\u003e\n\u003ctd\u003eDecember 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability Barrier\u003c\/td\u003e\n\u003ctd\u003eJ-Code Effective Date\u003c\/td\u003e\n\u003ctd\u003eJuly 1, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability Barrier\u003c\/td\u003e\n\u003ctd\u003eMAC Coverage Secured (as of Summer 2025)\u003c\/td\u003e\n\u003ctd\u003e4 of 7\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization Metric\u003c\/td\u003e\n\u003ctd\u003eRaised 2025 Net Sales Guidance\u003c\/td\u003e\n\u003ctd\u003e$490 million to $495 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization Metric\u003c\/td\u003e\n\u003ctd\u003eCash Position (End Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e$277.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSustained Advantage\u003c\/td\u003e\n\u003ctd\u003e36-Month Medication Independence Rate (vs. Control)\u003c\/td\u003e\n\u003ctd\u003e70% vs. 58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional clinical performance data includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMean IOP reduction of 11.3 mmHg (44%) at six months when iDose TR was implanted with cataract surgery (Phase 4 study).\u003c\/li\u003e\n\u003cli\u003eIn Phase 3 trials, IOP reductions from baseline over the first 3 months were 6.6-8.4 mmHg in the iDose TR arm.\u003c\/li\u003e\n\u003cli\u003eIn a single surgeon retrospective review (n=54 eyes at 3 months), mean IOP reduced from 19.6±3.8 mmHg preoperatively to 13.1±2.5 mmHg.\u003c\/li\u003e\n\u003cli\u003eThe percentage of eyes achieving IOP $\\le$15 mmHg increased from 11.1% preoperatively to 83.3% at 3 months in the retrospective review.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 8. Specialized Commercial and Training Infrastructure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to effectively train surgeons on complex new procedures, which is crucial for adoption of technologies like iDose TR.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eiDose TR contributed to U.S. Glaucoma franchise net sales of \u003cstrong\u003e$59.1 million\u003c\/strong\u003e in Q1 2025, a \u003cstrong\u003e41%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eU.S. Glaucoma franchise net sales reached \u003cstrong\u003e$72.3 million\u003c\/strong\u003e in Q2 2025, representing a \u003cstrong\u003e45%\u003c\/strong\u003e year-over-year growth.\u003c\/li\u003e\n\u003cli\u003eIn a Phase 4 study, iDose TR implanted in combination with cataract surgery achieved a mean IOP reduction of \u003cstrong\u003e11.3 mmHg\u003c\/strong\u003e, or \u003cstrong\u003e44%\u003c\/strong\u003e, at \u003cstrong\u003e6 months\u003c\/strong\u003e compared to baseline.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Glaucoma Franchise Net Sales\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$59.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Glaucoma Franchise YoY Growth\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Glaucoma Net Revenues\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$51.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eiDoseTR Sales Contribution\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$40 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients off Topical Meds (36 Months)\u003c\/td\u003e\n\u003ctd\u003eiDose TR vs. Timolol Control (Phase 3)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e70%\u003c\/strong\u003e vs. \u003cstrong\u003e58%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; competitors have sales forces, but Glaukos has built expertise specifically around MIGS and intracameral procedures.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGlaukos incurred approximately \u003cstrong\u003e$98.2 million\u003c\/strong\u003e of commercial personnel and discretionary spending in the year ending December 31, 2020, related primarily to existing sales infrastructure in glaucoma and training samples.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires significant investment in specialized field personnel and educational programs.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe company incurred approximately \u003cstrong\u003e$98.2 million\u003c\/strong\u003e in commercial personnel and discretionary spending in the year ending December 31, 2020.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management explicitly highlights ongoing efforts to expand surgeon training.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe establishment of a unique J-Code, \u003cstrong\u003eJ7355\u003c\/strong\u003e, for iDose TR became effective on July 1, 2024.\u003c\/li\u003e\n\u003cli\u003eManagement noted the expansion of iDose TR access to the \u003cstrong\u003eentire\u003c\/strong\u003e sales force as of Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; sales force expertise can be poached, but institutional knowledge takes time to build.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGlaukos Corporation (GKOS) - VRIO Analysis: 9. Integrated Glaucoma\/Corneal\/Retinal Focus\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eFocuses R\u0026amp;D and commercial efforts on a specific, high-need area of ophthalmology, allowing for platform technology reuse and deep domain expertise. Glaucoma net sales reached \u003cstrong\u003e$110.2 million\u003c\/strong\u003e in Q3 2025. The company has historically reinvested approximately \u003cstrong\u003e30%\u003c\/strong\u003e of all sales back into research and development activities.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; Alcon and J\u0026amp;J are broader, but Glaukos’s concentrated focus is a strength. The company's pipeline currently includes \u003cstrong\u003e14 Candidates\u003c\/strong\u003e, plus additional undisclosed programs across the three focus areas.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eDifficult; deep, specialized knowledge across multiple sub-specialties within one field is hard to replicate quickly. Research and development expenses for Q3 2025 were \u003cstrong\u003e$38.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; the entire company structure is aligned around these three disease categories. Cash and cash equivalents, short-term investments, and restricted cash totaled \u003cstrong\u003e$277.5 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; deep specialization often leads to better product development than broad diversification. FY 2025 net sales guidance is in the range of \u003cstrong\u003e$490 million to $495 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFocus Area\u003c\/th\u003e\n\u003cth\u003eLatest Quarterly Metric (Q3 2025)\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003cth\u003eComparison Period Metric\u003c\/th\u003e\n\u003cth\u003eComparison Value\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma Net Sales\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Glaucoma Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$110.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Growth (Q3 2025 vs Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorneal Health Net Sales\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Corneal Health Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Growth (Q3 2025 vs Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Performance\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Non-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~84%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Non-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~82%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eTotal Net Sales for Q3 2025 were \u003cstrong\u003e$133.5 million\u003c\/strong\u003e, a \u003cstrong\u003e38%\u003c\/strong\u003e increase year-over-year on a reported basis.\u003c\/li\u003e\n\u003cli\u003eU.S. Glaucoma net revenues for Q3 2025 were \u003cstrong\u003e$80.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePreliminary Net Sales Guidance for FY 2026 is \u003cstrong\u003e$600 million to $620 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for Q3 2025 were \u003cstrong\u003e$38.1 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e10%\u003c\/strong\u003e compared to Q3 2024's \u003cstrong\u003e$34.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516172689557,"sku":"gkos-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/gkos-vrio-analysis.png?v=1740177956","url":"https:\/\/dcf-model.com\/products\/gkos-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}